Revision: FDA Guidance for Remote Evaluations
Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Register now for ECA's GMP Newsletter
In April 2021, the US Food and Drug Administration (FDA) published a Guidance for Industry on remote evaluations. Anyone hoping at the time that the FDA would carry out these remote evaluations with the same or comparable status to an on-site inspection was mistaken. Even the title "Remote Interactive Evaluations" avoided the word inspection or audit. So, now the successor has been published as a draft. But not much has changed.
The only notable addition is that organisations must give their prior written consent for the remote interactive evaluation to be carried out. Measures that will be taken if this consent is not given are not mentioned.
And this time, comments on the draft are possible. In April 2021, it was merely pointed out that the document would be implemented immediately, without public participation in the development of the final guidelines.
Related GMP News
30.04.2025QP Declaration: New Q&As published
19.03.2025Root Cause Analysis: Again, problems discovered in GMP-Inspections
19.03.2025ICMRA publishes Hybrid Inspection Pilot Summary Report
19.03.2025From Burkholderia to Ethylene Glycol - a List of Deficiencies at a Manufacturer of OTC Products
19.03.2025Warning Letter - Deficiencies in the Control of Raw and Starting Materials
19.03.2025Inadequate Microbiological Testing of Nonsterile Products - FDA Warning Letter